Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
146.00    -6.80 (-4.45%)
Bid:
146.00
Ask:
153.40
Spread: 7.40 (5.068%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Elementis Trading Update

28 Oct 2016 07:00

ELEMENTIS PLC - Elementis Trading Update

ELEMENTIS PLC - Elementis Trading Update

PR Newswire

London, October 27

28 October 2016

Elementis – Trading Update

Elementis plc (ELM.L, “Elementis” or the “Group”), the Global Specialty Chemicals Company, today issues a trading update for the three months ended 30 September 2016.

Commenting on the Group’s performance Chief Executive Officer, Paul Waterman, said:

“We continue to focus on prioritising our strategic agenda, which we will present in more detail at the Group’s Capital Markets Day presentation on 14 November 2016. I am pleased to report continued progress in Specialty Products and while trading conditions for Chromium continued to be challenging, overall Group earnings per share for 2016 are expected to be in line with market expectations.

Specialty Products’ performance in the period was positive, with strong growth in Personal Care and improved performance in Latin America coatings.

In Chromium, although the environment internationally remains challenging, contribution margins in North America and the rest of the world were stable. We continue to look at options to increase efficiency to help offset the competitive effects of a stronger dollar.

Cash generation continues to be an important component of the Group’s performance and, as previously stated, the net cash balance at the end of the year is likely to be higher than at the same time last year which, under our progressive dividend policy, will have a positive effect on the special dividend.”

Specialty Products’ sales were 6 per cent higher than in the same period last year on a constant currency basis, and 4 per cent on a reported basis. The remainder of this business commentary refers to constant currency sales.

In Coatings, Asia Pacific sales were 5 per cent ahead of the prior year as demand in China continued to reflect solid underlying growth. Sales in Latin America showed significant growth in the period, despite ongoing economic challenges in Brazil. The business benefited from new business wins at key accounts in Brazil, Mexico and Chile, which resulted in sales being 38 per cent higher than in the same period last year. Sales in North America were at a similar level to the comparator period, as overall demand continued to be negatively influenced by the impact of the strong dollar on North American exporters. In Europe, following a relatively strong second quarter (+4 per cent), sales in the period were 5 per cent lower than in the same period last year. We saw reduced consumption across Europe through our distributor channel whilst sales to Eastern Europe were also lower.

In Personal Care, where the Group has recently added more resources, sales were 38 per cent higher than in the same period last year. Excellent progress was made in growing sales of hectorite products in colour cosmetics and antiperspirants, while expanding sales geographically also showed good progress, particularly in Italy, China, India and Brazil.

In Oilfield Drilling, sales were 4 per cent lower than in the same period last year as demand patterns continued to remain relatively stable.

In Chromium, sales were 4 per cent lower than in the same period last year, on 3 per cent higher volumes, which was due to a continuation of the more challenging environment outside of North America, as reported in previous announcements. Compared to the second quarter, contribution margins in the period were relatively stable in North America and improved for sales outside of the region, as a result of a better product mix.

Consistent with the strategy to reduce activity in Surfactants over time, sales in the period were 14 per cent lower than in the same period last year and operating profit was consistent with the previously reported near break-even run rate in the first six months of the year.

The Group’s tax rate for the full year is expected to be lower than it was for the first six months of the year, due to changes in the geographic mix of profits, but overall Group earnings per share for 2016 are expected to be in line with market expectations. The Group’s balance sheet remains strong, with robust operating cash generation continuing to be a positive feature of the Group’s performance. Consequently, the Group’s year end net cash balance is expected to be higher than the $74 million reported at the end of 2015.

END

Enquiries
Elementis plc Paul Waterman, CEO Brian Taylorson, CFO Ralph Hewins, CFO-DesignateTel: +44 (0) 20 7067 2999
FTI Consulting Deborah Scott Matthew ColeTel: +44 (0) 20 3727 1000
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.